DK2968346T3 - Fremgangsmåder og sammensætninger til modulation af gamma-glutamylcyklus - Google Patents
Fremgangsmåder og sammensætninger til modulation af gamma-glutamylcyklus Download PDFInfo
- Publication number
- DK2968346T3 DK2968346T3 DK14763483.6T DK14763483T DK2968346T3 DK 2968346 T3 DK2968346 T3 DK 2968346T3 DK 14763483 T DK14763483 T DK 14763483T DK 2968346 T3 DK2968346 T3 DK 2968346T3
- Authority
- DK
- Denmark
- Prior art keywords
- modulating
- gamma
- compositions
- methods
- glutamyl cycle
- Prior art date
Links
- 125000002642 gamma-glutamyl group Chemical group 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801709P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030053 WO2014145314A2 (en) | 2013-03-15 | 2014-03-15 | Methods and compositions for gamma-glutamyl cycle modulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2968346T3 true DK2968346T3 (da) | 2024-05-06 |
Family
ID=51529989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14763483.6T DK2968346T3 (da) | 2013-03-15 | 2014-03-15 | Fremgangsmåder og sammensætninger til modulation af gamma-glutamylcyklus |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9630936B2 (da) |
| EP (1) | EP2968346B1 (da) |
| JP (2) | JP6458000B2 (da) |
| KR (2) | KR20160003652A (da) |
| CN (1) | CN105246483A (da) |
| AU (2) | AU2014233168B2 (da) |
| CA (2) | CA3232320A1 (da) |
| DK (1) | DK2968346T3 (da) |
| EA (1) | EA030611B1 (da) |
| FI (1) | FI2968346T3 (da) |
| IL (2) | IL283717B (da) |
| WO (1) | WO2014145314A2 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014233168B2 (en) * | 2013-03-15 | 2018-11-22 | Cancer Research Technology, Llc | Methods and compositions for Gamma-glutamyl cycle modulation |
| US9802888B2 (en) | 2013-03-22 | 2017-10-31 | University Of Hawaii | STAT3 inhibitors |
| US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| CN107382903B (zh) * | 2017-05-22 | 2021-02-26 | 重庆南松凯博生物制药有限公司 | 一种抗癌药物中间体的制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4011233A (en) | 1973-06-28 | 1977-03-08 | Givaudan Corporation | 2-methyl-2-(4-methyl-3-pentene-1-yl) thiazolidine |
| JPS56133216A (en) * | 1980-03-24 | 1981-10-19 | Senjiyu Seiyaku Kk | Antitumor agent |
| JPS57128625A (en) * | 1981-01-30 | 1982-08-10 | Rikagaku Kenkyusho | Carcinostatic |
| ATE80801T1 (de) * | 1984-12-18 | 1992-10-15 | Clark Pharma Dev | Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln. |
| HU200177B (en) * | 1985-06-18 | 1990-04-28 | Biogal Gyogyszergyar | Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds |
| JP2717257B2 (ja) * | 1988-03-19 | 1998-02-18 | 参天製薬株式会社 | 光学活性化合物の製造法 |
| US4970221A (en) * | 1989-07-28 | 1990-11-13 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| NL9001955A (nl) * | 1990-09-05 | 1992-04-01 | Cedona Pharm Bv | Nieuwe thiazolidinederivaten. |
| JPH04169858A (ja) | 1990-11-02 | 1992-06-17 | Toyota Motor Corp | 力学量センサ |
| US7425635B2 (en) * | 1997-08-07 | 2008-09-16 | University Of Utah Research Foundation | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US20080220441A1 (en) * | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| JP5042444B2 (ja) | 2002-03-22 | 2012-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌の処置におけるヘミアスタリン誘導体およびその利用法 |
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| ES2284054T3 (es) | 2003-10-14 | 2007-11-01 | Pharmacia Corporation | Compuestos de pirazinona sustituidos para el tratamiento de la inflamacion. |
| DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| US20060014740A1 (en) * | 2003-11-18 | 2006-01-19 | Miller Duane D | Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof |
| US7307093B2 (en) | 2003-11-18 | 2007-12-11 | The University Of Tennessee Research Foundation | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof |
| KR100590530B1 (ko) | 2003-12-10 | 2006-06-15 | 삼성전자주식회사 | 수직자기기록매체 |
| MXPA06007007A (es) * | 2003-12-18 | 2007-06-08 | Zoser B Salama | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. |
| BRPI0507612A (pt) * | 2004-02-11 | 2007-07-03 | Univ Ohio State Res Found | análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes |
| KR20060014740A (ko) | 2004-08-12 | 2006-02-16 | 조정래 | 항균 수처리기 |
| US7702430B2 (en) * | 2004-11-19 | 2010-04-20 | The Board Of Regents Of The University Of Texas System | Method for designing a potential inhibitor of glutathione-aldehyde conjugate binding to aldose reductase |
| DE102004055998A1 (de) * | 2004-11-19 | 2006-05-24 | Rheinische Friedrich-Wilhelms-Universität Bonn | Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie |
| JP4446922B2 (ja) | 2005-04-21 | 2010-04-07 | 富士通メディアデバイス株式会社 | フィルタおよび分波器 |
| CA2927656C (en) | 2005-10-07 | 2019-09-24 | Exelixis, Inc. | Mek inhibitors and methods of their use |
| JP4493588B2 (ja) | 2005-11-30 | 2010-06-30 | 京セラミタ株式会社 | 画像形成装置 |
| WO2007139573A1 (en) * | 2006-05-31 | 2007-12-06 | The Trustees Of Columbia University In The City Of New York | Ribosome and rna display of biologically active small molecules |
| US20090233972A1 (en) * | 2008-03-12 | 2009-09-17 | Yat Sun Or | Substituted heterocycles as anti-infectives |
| JP2009233972A (ja) | 2008-03-26 | 2009-10-15 | Fujifilm Corp | 液体吐出装置 |
| KR100935543B1 (ko) | 2008-04-02 | 2010-01-07 | (주)예기산업 | 자연순환방식의 프리히팅장치 및 이를 이용한프리히팅시스템 |
| CN102131505A (zh) * | 2008-06-20 | 2011-07-20 | 阿斯利康(瑞典)有限公司 | 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物 |
| JP5030934B2 (ja) | 2008-12-18 | 2012-09-19 | 株式会社ケーヒン | エンジンの吸気制御装置における制御ケースの呼吸構造 |
| CN102300790B (zh) | 2009-01-29 | 2013-10-16 | 平田机工株式会社 | 工件保持移送装置 |
| MX2012002993A (es) * | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| KR20110092501A (ko) | 2010-02-09 | 2011-08-18 | 주식회사 캐러스 | 하이브리드 항균 펩타이드 및 이의 용도 |
| KR101395146B1 (ko) * | 2011-02-09 | 2014-05-16 | 부산대학교 산학협력단 | 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
| CA2873093A1 (en) * | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| AU2014233168B2 (en) | 2013-03-15 | 2018-11-22 | Cancer Research Technology, Llc | Methods and compositions for Gamma-glutamyl cycle modulation |
-
2014
- 2014-03-15 AU AU2014233168A patent/AU2014233168B2/en active Active
- 2014-03-15 KR KR1020157029230A patent/KR20160003652A/ko active Application Filing
- 2014-03-15 IL IL283717A patent/IL283717B/en unknown
- 2014-03-15 EA EA201500941A patent/EA030611B1/ru unknown
- 2014-03-15 US US14/214,888 patent/US9630936B2/en active Active
- 2014-03-15 FI FIEP14763483.6T patent/FI2968346T3/fi active
- 2014-03-15 DK DK14763483.6T patent/DK2968346T3/da active
- 2014-03-15 JP JP2016503319A patent/JP6458000B2/ja active Active
- 2014-03-15 EP EP14763483.6A patent/EP2968346B1/en active Active
- 2014-03-15 CN CN201480028110.7A patent/CN105246483A/zh active Pending
- 2014-03-15 CA CA3232320A patent/CA3232320A1/en active Pending
- 2014-03-15 CA CA2909510A patent/CA2909510C/en active Active
- 2014-03-15 WO PCT/US2014/030053 patent/WO2014145314A2/en active Application Filing
- 2014-03-15 KR KR1020217038087A patent/KR20210144942A/ko not_active Application Discontinuation
-
2015
- 2015-09-16 IL IL241620A patent/IL241620B/en active IP Right Grant
-
2017
- 2017-04-24 US US15/495,496 patent/US10323009B2/en active Active
-
2018
- 2018-12-21 JP JP2018239199A patent/JP6739509B2/ja active Active
-
2019
- 2019-02-22 AU AU2019201264A patent/AU2019201264B2/en active Active
- 2019-06-17 US US16/443,795 patent/US11186555B2/en active Active
-
2021
- 2021-11-29 US US17/537,266 patent/US20220324820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL241620B (en) | 2021-06-30 |
| EP2968346A4 (en) | 2017-02-08 |
| US20140275187A1 (en) | 2014-09-18 |
| WO2014145314A3 (en) | 2014-11-13 |
| CN105246483A (zh) | 2016-01-13 |
| US11186555B2 (en) | 2021-11-30 |
| EA030611B1 (ru) | 2018-08-31 |
| EP2968346B1 (en) | 2024-02-07 |
| FI2968346T3 (fi) | 2024-05-06 |
| JP6739509B2 (ja) | 2020-08-12 |
| KR20210144942A (ko) | 2021-11-30 |
| EP2968346A2 (en) | 2016-01-20 |
| AU2019201264A1 (en) | 2019-03-14 |
| US9630936B2 (en) | 2017-04-25 |
| WO2014145314A2 (en) | 2014-09-18 |
| IL283717A (en) | 2021-07-29 |
| CA2909510A1 (en) | 2014-09-18 |
| US20220324820A1 (en) | 2022-10-13 |
| US20190359580A1 (en) | 2019-11-28 |
| IL283717B (en) | 2022-09-01 |
| EA201500941A1 (ru) | 2016-07-29 |
| CA2909510C (en) | 2024-04-02 |
| US10323009B2 (en) | 2019-06-18 |
| JP2016515531A (ja) | 2016-05-30 |
| JP6458000B2 (ja) | 2019-01-23 |
| CA3232320A1 (en) | 2014-09-18 |
| KR20160003652A (ko) | 2016-01-11 |
| AU2014233168A1 (en) | 2015-11-05 |
| AU2014233168B2 (en) | 2018-11-22 |
| AU2019201264B2 (en) | 2020-07-16 |
| JP2019065031A (ja) | 2019-04-25 |
| US20170226070A1 (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3524680T3 (da) | Sammensætninger og fremgangsmåder til modulation af ttr-ekspression | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK2981822T3 (da) | Sammensætninger og fremgangsmåder til vækstfaktormodulation | |
| DK3125927T3 (da) | Fremgangsmåder og sammensætninger til immunmodulering | |
| DK3283080T3 (da) | Sammensætninger til modulation af c9orf72-ekspression | |
| DK3604294T3 (da) | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter | |
| DK3036256T3 (en) | Modulation af tumorimmunitet | |
| DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK2953972T3 (da) | Fremgangsmåde til udvælgelse af antistoffer mod bcma | |
| DK2906696T3 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
| DK3083540T3 (da) | Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner | |
| DK3300610T3 (da) | Fremgangsmåde til fraktionering af opløselige ærter | |
| HK1218659A1 (zh) | 用於調節 表達的組合物和方法 | |
| DK2922955T3 (da) | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression | |
| DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3363805T3 (da) | Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner | |
| DK3063300T3 (da) | Mikropeptider og anvendelse deraf til modulering af genekspression | |
| DK2994991T3 (da) | Apparat der anvender spoleinduktansbestemmelse og fremgangsmåde til drift af apparatet | |
| DK3520591T3 (da) | Fremgangsmåde til spredning af gødningsmidler | |
| DK2870450T3 (da) | Fremgangsmåde til bestemmelse af modalparametre |